Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure (ASTRONAUT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00894387
First received: May 5, 2009
Last updated: October 15, 2013
Last verified: October 2013
  Purpose

This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart failure (CHF) patients hospitalized for an episode of acute decompensated heart failure.


Condition Intervention Phase
Acute Decompensated Heart Failure
Congestive Heart Failure
Drug: Aliskiren
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the 6 Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality When Initiated Early After Hospitalization for Acute Decompensated Heart Failure

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Time to Event Analysis: Number of Patients Experienced the First Confirmed Occurrence of Either Cardiovascular Death or Heart Failure (HF) Re-hospitalization Within 6 Months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Time to first confirmed occurrence of either cardiovascular death or heart failure re-hospitalization within 6 months of randomization was the primary efficacy variable. For the primary efficacy analysis, an event will be considered for the analysis if it occurs on or before Day 190 (189 days from randomization). The primary composite endpoint is the the composite of cardiovascular death or heart faliure re-hospitalization within 6 months.


Secondary Outcome Measures:
  • Time to Event Analysis: Number of Patients Experienced the First Confirmed Occurrence of Either Cardiovascular Death or Heart Failure (HF) Re-hospitalization Within 12 Months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Time to first confirmed occurrence of either cardiovascular death or heart failure re-hospitalization within 12 months of randomization was the key secondary efficacy variable. For the primary efficacy analysis, an event will be considered for the analysis if it occurs on or before Day 395 (394 days from randomization). The secondary composite endpoint is the the composite of cardiovascular death or heart faliure re-hospitalization within 12 months.

  • Change From Baseline in the Clinical Summary Score to 1 Month, 6 Months and 12 Months [ Time Frame: Baseline, 1 months, 6 months and 12 months ] [ Designated as safety issue: No ]
    Symptom reduction and reduction in physical limitations was assessed using the clinical summary score of the Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ is a self-administered questionnaire and contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Health-Related Quality of Life (QoL), including limitations, frequency, bother, change in condition, understanding, levels of enjoyment and satisfaction. Each scale score was calculated as the mean of its item scores and transformed to a 0-100 scale, with higher score indicating higher level of functioning. A score of 100 represents perfect health whereas a score of 0 represents death. A positive change in score from baseline indicates an improvement.

  • Time to Event Analysis: Number of Patients With First Cardiovascular (CV) Event Hospitalized for an Acute Heart Faliure (AHF) Event Within 6 Months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    A cardiovascular event defined as CV death, heart faliure re-hospitalization, non-fatal myocardial infarction (MI), nonfatal stroke, sudden death with resuscitation.

  • Time to Event Analysis: Number of Patients With All-cause Mortality Hospitalized for an AHF Event Within 12 Months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Level at 1 Month, 6 Months, and 12 Months [ Time Frame: Baseline, 1 month, 6 months and 12 months ] [ Designated as safety issue: No ]
    The reported Least square means, and Confidential Interval were from a repeated measures model on log transformed NT-proBNP data containing treatment, visit, and region as factors, log baseline NT-proBNP as a continuous covariate and treatment by visit and visit by log baseline NT-proBNP as interaction terms.

  • Time to Event Analysis: Number of Patients With First Cardiovascular (CV) Event Hospitalized for an Acute Heart Faliure (AHF) Event Within 12 Months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    A cardiovascular event defined as CV death, heart faliure re-hospitalization, non-fatal myocardial infarction (MI), nonfatal stroke, sudden death with resuscitation.


Enrollment: 1639
Study Start Date: May 2009
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aliskiren
Randomized patients in this arm received, Aliskiren 150 mg once daily for 2 weeks. From week 2 upto 6 months , patients who could tolerate study medication were up-titrated to aliskiren 300 mg once daliy.
Drug: Aliskiren
Aliskiren 150 mg and Aliskiren 300 mg
Other Names:
  • Aliskiren®,
  • Tekturna®,
  • Rasilez®,
  • SPP100
Placebo Comparator: Placebo
Randomized patients in this arm received matching placebo of Aliskiren. At week 2, Patients who could tolerate study medication were up-titrated to matching placebo of 300 mg aliskiren.
Drug: Placebo
Placebo

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Patient hospitalized with a primary diagnosis of worsening heart failure ≥ 18 years of age, male or female.
  • Patients with a diagnosis of acute heart failure expressed by symptoms (dyspnea or fatigability - NYHA Class III-IV) and signs of fluid overload (i.e., jugular venous distension, edema or positive rales auscultation or pulmonary congestion on chest x-ray) at the time of hospitalization.

    • LVEF < 40% (measured within the last 6 months).
    • Hospitalization for ADHF and remain "stabilized" for at least 6 hours (defined as SBP ≥ 110 mm Hg after acute decompensated episode) and did not receive IV vasodilators (other than nitrates) and/or IV inotropic drugs at anytime from ADHF presentation to time of randomization.
  • Elevated BNP at Visit 1 or at randomization (BNP ≥ 400 pg/ml).
  • Patients with a history of chronic heart failure on standard therapy defined as requiring HF treatment for at least 30 days before the current hospitalization (NYHA Class II - IV).

Exclusion Criteria:

  • Patients that required any use of IV vasodilators (except nitrates), and/or any IV inotropic therapy from the time of presentation for worsening HF to randomization.
  • Concomitant use of ACEI and ARB at randomization.
  • Right heart failure due to pulmonary disease.
  • Diagnosis of postpartum cardiomyopathy.
  • Myocardial infarction or cardiac surgery, including percutaneous transluminal coronary angioplasty (PTCA), within past 3 months.
  • Patients with a history of heart transplant or who are on a transplant list.
  • Unstable angina or coronary artery disease likely to require coronary artery bypass graft (CABG) or PTCA before randomization.

Other protocol-defined inclusion/exclusion criteria applied.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00894387

  Hide Study Locations
Locations
United States, Alabama
Novartis Investigative Site
Mobile, Alabama, United States, 36608
United States, Arizona
Novartis Investigative Site
Tucson, Arizona, United States, 85723-0001
United States, California
Novartis Investigative Site
Los Angeles, California, United States, 90073
Novartis Investigative Site
San Diego, California, United States, 92103
Novartis Investigative Site
Sylmar, California, United States, 91342
Novartis Investigative Site
Torrance, California, United States, 90502
United States, Connecticut
Novartis Investigative Site
Hartford, Connecticut, United States, 06102-5037
United States, District of Columbia
Novartis Investigative Site
Washington, District of Columbia, United States, 20037
Novartis Investigative Site
Washington, District of Columbia, United States, 20010-2975
United States, Florida
Novartis Investigative Site
Jacksonville, Florida, United States, 32207
United States, Georgia
Novartis Investigative Site
Macon, Georgia, United States, 31201
United States, Illinois
Novartis Investigative Site
Oakbrook Terrace, Illinois, United States, 60181
United States, Iowa
Novartis Investigative Site
Iowa City, Iowa, United States, 52245
United States, Louisiana
Novartis Investigative Site
Lafayette, Louisiana, United States, 70501
United States, Michigan
Novartis Investigative Site
Detroit, Michigan, United States, 48202
Novartis Investigative Site
Kalamazoo, Michigan, United States, 49048
United States, Missouri
Novartis Investigative Site
St. Louis, Missouri, United States, 63110
United States, New Jersey
Novartis Investigative Site
Cherry Hill, New Jersey, United States, 08034
Novartis Investigative Site
Newark, New Jersey, United States, 07103-2714
United States, New York
Novartis Investigative Site
Bronx, New York, United States, 10461
Novartis Investigative Site
Buffalo, New York, United States, 14215
Novartis Investigative Site
Buffalo, New York, United States, 14203
Novartis Investigative Site
Saratoga Springs, New York, United States, 12866
United States, North Carolina
Novartis Investigative Site
Chapel Hill, North Carolina, United States, 27599-7075
United States, Ohio
Novartis Investigative Site
Cincinnati, Ohio, United States, 45267-0585
Novartis Investigative Site
Cincinnati, Ohio, United States, 45219
Novartis Investigative Site
Cleveland, Ohio, United States, 44109-1998
United States, Pennsylvania
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19102-1192
Novartis Investigative Site
Philadelphia, Pennsylvania, United States, 19140
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States, 15212
United States, South Carolina
Novartis Investigative Site
Charleston, South Carolina, United States, 29403
United States, South Dakota
Novartis Investigative Site
Rapid City, South Dakota, United States, 57701
United States, Tennessee
Novartis Investigative Site
Springfield, Tennessee, United States, 37172
United States, Texas
Novartis Investigative Site
Brownsville, Texas, United States, 78520
United States, Virginia
Novartis Investigative Site
Charlottesville, Virginia, United States, 22908
Novartis Investigative Site
Richmond, Virginia, United States, 23249
Novartis Investigative Site
Richmond, Virginia, United States, 23298
Argentina
Novartis Investigative Site
San Nicolas, Buenos Aires, Argentina, B2900IIC
Novartis Investigative Site
Posadas, Misiones, Argentina, N3300AHX
Novartis Investigative Site
Rosario, Santa Fe, Argentina, S2001ODA
Novartis Investigative Site
Rosario, Santa Fe, Argentina, S2000DSV
Novartis Investigative Site
San Miguel de Tucuman, Tucuman, Argentina, T4000JCU
Novartis Investigative Site
Buenos aires, Argentina, C1210AAP
Novartis Investigative Site
Buenos Aires, Argentina, W3400ABH
Novartis Investigative Site
Buenos Aires, Argentina, C1094AAD
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina, C1201AAO
Novartis Investigative Site
Buenos Aires, Argentina, B1650CSQ
Novartis Investigative Site
Buenos Aires, Argentina, B1708KCH
Novartis Investigative Site
Buenos Aires, Argentina, C1428AQK
Novartis Investigative Site
Buenos Aires, Argentina, C1050AAK
Novartis Investigative Site
Cordoba, Argentina, X5000AAI
Novartis Investigative Site
Cordoba, Argentina, X5006IKK
Novartis Investigative Site
Corrientes, Argentina, 3400
Novartis Investigative Site
Corrientes, Argentina, W3400
Novartis Investigative Site
Corrientes, Argentina, W3400CBI
Novartis Investigative Site
Quilmes, Argentina, 1878
Novartis Investigative Site
Santa Fe, Argentina, 3000
Novartis Investigative Site
Santa Fe, Argentina, S2004CMW
Novartis Investigative Site
Tucuman, Argentina, T4000NIJ
Belgium
Novartis Investigative Site
Antwerpen, Belgium, 2020
Novartis Investigative Site
Brasschaat, Belgium, 2930
Novartis Investigative Site
Genk, Belgium, 3600
Novartis Investigative Site
Gent, Belgium, 9000
Novartis Investigative Site
Hasselt, Belgium, 3500
Novartis Investigative Site
Huy, Belgium, 4500
Novartis Investigative Site
Leuven, Belgium, 3000
Novartis Investigative Site
Mechelen, Belgium, 2800
Novartis Investigative Site
Mol, Belgium, 2400
Novartis Investigative Site
Namur, Belgium, 5000
Brazil
Novartis Investigative Site
Belo Horizonte, MG, Brazil
Novartis Investigative Site
Belo Horizonte, MG, Brazil, 30150-221
Novartis Investigative Site
Belo Horizonte, MG, Brazil, 20180-090
Novartis Investigative Site
Londrina, PR, Brazil, 86051-990
Novartis Investigative Site
Rio de Janeiro, RJ, Brazil, 22261-010
Novartis Investigative Site
Porto Alegre, RS, Brazil, 90610-000
Novartis Investigative Site
Campinas, SP, Brazil, 13060-904
Novartis Investigative Site
Sao Jose do Rio Preto, SP, Brazil, 15150-210
Novartis Investigative Site
São Paulo, SP, Brazil, 05403-000
Canada, Newfoundland and Labrador
Novartis Investigative Site
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Canada, Nova Scotia
Novartis Investigative Site
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
Novartis Investigative Site
Ottawa, Ontario, Canada, K1Y 4W7
Novartis Investigative Site
Toronto, Ontario, Canada, M5B 1W8
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H3A 1A1
Novartis Investigative Site
Montreal, Quebec, Canada, H3T 1E2
Colombia
Novartis Investigative Site
Barranquilla, Atlantico, Colombia
Novartis Investigative Site
Bogotá, Cundinamarca, Colombia
Novartis Investigative Site
Barranquilla, Colombia
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Bogotá, Colombia, 0000
Novartis Investigative Site
Cali, Colombia
Novartis Investigative Site
Florida Blanca, Colombia
Czech Republic
Novartis Investigative Site
Hradec Kralove, CZE, Czech Republic, 500 05
Novartis Investigative Site
Brno, Czech Republic, 636 00
Novartis Investigative Site
Brno - Bohunice, Czech Republic, 625 00
Novartis Investigative Site
Olomouc, Czech Republic, 775 20
Novartis Investigative Site
Prague 4, Czech Republic, 146 24
Novartis Investigative Site
Prague 5, Czech Republic, 150 00
Novartis Investigative Site
Praha 10, Czech Republic, 100 34
Novartis Investigative Site
Praha 2, Czech Republic, 128 08
Novartis Investigative Site
Slany, Czech Republic, 27401
Novartis Investigative Site
Teplice, Czech Republic, 415 29
Novartis Investigative Site
Znojmo, Czech Republic, 669 02
Finland
Novartis Investigative Site
Jyvaskyla, Finland, FIN-40620
Novartis Investigative Site
Turku, Finland, 20520
France
Novartis Investigative Site
Bordeaux Cedex, France, 33075
Novartis Investigative Site
Grenoble, France, 38043
Novartis Investigative Site
Le Chesnay, France
Novartis Investigative Site
Paris, France, 75013
Novartis Investigative Site
Paris, France, 75571
Novartis Investigative Site
Pessac Cedex, France, 33604
Novartis Investigative Site
Pontoise, France, F-95300
Novartis Investigative Site
Toulouse Cedex, France, 31059
Germany
Novartis Investigative Site
Augsburg, Germany, 86156
Novartis Investigative Site
Bad Bevensen, Germany, 29549
Novartis Investigative Site
Bad Nauheim, Germany, 61231
Novartis Investigative Site
Berlin, Germany, 12621
Novartis Investigative Site
Berlin, Germany, 10249
Novartis Investigative Site
Berlin, Germany, 13578
Novartis Investigative Site
Berlin, Germany, 13347
Novartis Investigative Site
Berlin, Germany, 10098
Novartis Investigative Site
Berlin, Germany, 13353
Novartis Investigative Site
Bischofswerda, Germany, 01877
Novartis Investigative Site
Bonn, Germany, 53105
Novartis Investigative Site
Bremen, Germany, 28277
Novartis Investigative Site
Cloppenburg, Germany, 49661
Novartis Investigative Site
Cottbus, Germany, 03048
Novartis Investigative Site
Dessau, Germany, D-06822
Novartis Investigative Site
Detmold, Germany, 32756
Novartis Investigative Site
Dortmund, Germany, 44137
Novartis Investigative Site
Dresden, Germany, 01067
Novartis Investigative Site
Frankfurt, Germany, 60316
Novartis Investigative Site
Frankfurt, Germany, 60488
Novartis Investigative Site
Greifswald, Germany, 17475
Novartis Investigative Site
Halle/'Saale, Germany, 06120
Novartis Investigative Site
Hamburg, Germany, 20246
Novartis Investigative Site
Herne, Germany, 44649
Novartis Investigative Site
Herrsching, Germany, 82211
Novartis Investigative Site
Jena, Germany, 07740
Novartis Investigative Site
Konstanz, Germany, 78464
Novartis Investigative Site
Köln, Germany, 50924
Novartis Investigative Site
Langen, Germany, 63225
Novartis Investigative Site
Ludwigslust, Germany, 19288
Novartis Investigative Site
Magdeburg, Germany, 39120
Novartis Investigative Site
Merseburg, Germany, 06217
Novartis Investigative Site
Muenchen, Germany, 81377
Novartis Investigative Site
Nordhorn, Germany, 48527
Novartis Investigative Site
Paderborn, Germany, 33098
Novartis Investigative Site
Quedlinburg, Germany, 06484
Novartis Investigative Site
Regensburg, Germany, 93053
Novartis Investigative Site
Rostock, Germany, 18057
Novartis Investigative Site
Sömmerda, Germany, 99610
Novartis Investigative Site
Weiden, Germany, 92637
Hungary
Novartis Investigative Site
Pecs, Baranya, Hungary, 7621
Novartis Investigative Site
Balatonfured, Hungary, H-8231
Novartis Investigative Site
Budapest, Hungary, H-1106
Novartis Investigative Site
Budapest, Hungary, 1027
Novartis Investigative Site
Budapest, Hungary, 1096
Novartis Investigative Site
Hodmezovasarhely, Hungary, 6800
Novartis Investigative Site
Nagykanizsa, Hungary, 8800
Novartis Investigative Site
Szolnok, Hungary, H-5000
Novartis Investigative Site
Zalaegerszeg, Hungary, 8900
India
Novartis Investigative Site
Secunderabad, Andhra Pradesh, India, 500003
Novartis Investigative Site
Vadodara, Gujrat, India, 390015
Novartis Investigative Site
Bangalore, Karnataka, India, 560099
Novartis Investigative Site
Bangalore, Karnataka, India, 560 069
Novartis Investigative Site
Mangalore, Karnataka, India, 575002
Novartis Investigative Site
Kochi, Kerala, India, 682 026
Novartis Investigative Site
Indore, M.p., India, 452001
Novartis Investigative Site
Mumbai, Maharashtra, India, 400 022
Novartis Investigative Site
Nagpur, Maharashtra, India, 440010
Novartis Investigative Site
Nagpur, Maharashtra, India, 440012
Novartis Investigative Site
Pune, Maharashtra, India, 411004
Novartis Investigative Site
Pune, Maharashtra, India, 411030
Novartis Investigative Site
Pune, Maharashtra, India, 411011
Novartis Investigative Site
Coimbatore, Tamil Nadu, India, 641037
Novartis Investigative Site
Coimbatore, Tamil Nadu, India, 641014
Novartis Investigative Site
Bangalore, India, 560 034
Novartis Investigative Site
Hyderabad, India, 500 063
Novartis Investigative Site
New Delhi, India, 110 025
Israel
Novartis Investigative Site
Ashkelon, Israel, 78278
Novartis Investigative Site
Hadera, Israel, 38100
Novartis Investigative Site
Haifa, Israel, 34362
Novartis Investigative Site
Jerusalem, Israel, 91120
Novartis Investigative Site
Nazareth, Israel, 16100
Novartis Investigative Site
Safed, Israel, 13100
Novartis Investigative Site
Tel-Aviv, Israel, 64239
Italy
Novartis Investigative Site
Pavia, (pv), Italy, 27100
Novartis Investigative Site
Verona, (vr), Italy, 37126
Novartis Investigative Site
Bologna, BO, Italy, 40138
Novartis Investigative Site
Brescia, BS, Italy, 25123
Novartis Investigative Site
Cremona, CR, Italy, 26100
Novartis Investigative Site
Catania, CT, Italy, 95123
Novartis Investigative Site
Lagosanto, FE, Italy, 44023
Novartis Investigative Site
Foggia, FG, Italy, 71100
Novartis Investigative Site
Firenze, FI, Italy, 50141
Novartis Investigative Site
Grosseto, GR, Italy, 58100
Novartis Investigative Site
Pozzilli, IS, Italy, 86077
Novartis Investigative Site
Casarano, LE, Italy, 73042
Novartis Investigative Site
Lecce, LE, Italy, 73100
Novartis Investigative Site
Scorrano, LE, Italy, 73020
Novartis Investigative Site
Monza, MB, Italy, 20900
Novartis Investigative Site
Legnano, MI, Italy, 20025
Novartis Investigative Site
Milano, MI, Italy, 20157
Novartis Investigative Site
Palermo, PA, Italy, 90146
Novartis Investigative Site
Perugia, PG, Italy, 06129
Novartis Investigative Site
Parma, PR, Italy, 43100
Novartis Investigative Site
Albano Laziale, RM, Italy, 00041
Novartis Investigative Site
Roma, RM, Italy, 00189
Novartis Investigative Site
Roma, RM, Italy, 00185
Novartis Investigative Site
Rimini, RN, Italy, 47900
Novartis Investigative Site
Siena, SI, Italy, 53100
Novartis Investigative Site
Legnago, VR, Italy, 37045
Philippines
Novartis Investigative Site
Quezon City, Metro Manila, Philippines, 1109
Novartis Investigative Site
Manila, Philippines, 1000
Novartis Investigative Site
Quezon City, Philippines, 1100
Poland
Novartis Investigative Site
Grodzisk Wielkopolski, Poland, 62-065
Novartis Investigative Site
Klodzko, Poland, 57-300
Novartis Investigative Site
Kraków, Poland, 31-531
Novartis Investigative Site
Lublin, Poland, 20-954
Novartis Investigative Site
Lódz, Poland, 91-347
Novartis Investigative Site
Ruda Slaska, Poland, 41-703
Novartis Investigative Site
Swidnica, Poland, 58-100
Novartis Investigative Site
Szczecin, Poland, 70-111
Novartis Investigative Site
Walbrzych, Poland, 58-309
Novartis Investigative Site
Warszawa, Poland, 03-242
Novartis Investigative Site
Warszawa, Poland, 04-628
Novartis Investigative Site
Wroclaw, Poland, 50-367
Novartis Investigative Site
Wroclaw, Poland, 50-981
Novartis Investigative Site
Zabrze, Poland, 41-800
Novartis Investigative Site
Zamosc, Poland, 22-400
Romania
Novartis Investigative Site
Bucuresti, District 1, Romania, 014461
Novartis Investigative Site
Bucharest, Romania, 020125
Novartis Investigative Site
Bucharest, Romania, 021659
Novartis Investigative Site
Craiova, Romania, 200642
Novartis Investigative Site
Timisoara, Romania, 300310
Novartis Investigative Site
Tirgoviste, Romania, 130083
Russian Federation
Novartis Investigative Site
Lubertsi, Russian Federation, 140006
Novartis Investigative Site
Moscow, Russian Federation, 111539
Novartis Investigative Site
Moscow, Russian Federation, 117198
Novartis Investigative Site
Moscow, Russian Federation, 127473
Novartis Investigative Site
Moscow, Russian Federation, 119881
Novartis Investigative Site
Moscow, Russian Federation, 115487
Novartis Investigative Site
Moscow, Russian Federation, 127644
Novartis Investigative Site
Moscow, Russian Federation, 109377
Novartis Investigative Site
Moscow, Russian Federation, 121552
Novartis Investigative Site
Nizhnii Novgorod, Russian Federation, 603000
Novartis Investigative Site
S.-Petersburg, Russian Federation, 198205
Novartis Investigative Site
S.-Petersburg, Russian Federation, 192242
Novartis Investigative Site
S.-Petersburg, Russian Federation, 196247
Novartis Investigative Site
S.-Petersburg, Russian Federation, 195197
Novartis Investigative Site
Saint Petersburg, Russian Federation, 195067
Novartis Investigative Site
Saint Petersburg, Russian Federation, 199106
Novartis Investigative Site
Saint-Petersburg, Russian Federation, 198013
Novartis Investigative Site
Saint-Petersburg, Russian Federation, 193312
Novartis Investigative Site
Saint-Petersburg, Russian Federation, 197341
Novartis Investigative Site
Sankt-Peterburg, Russian Federation, 197022
Novartis Investigative Site
Saratov, Russian Federation, 410012
Novartis Investigative Site
Saratov, Russian Federation, 410028
Novartis Investigative Site
St.Petersburg, Russian Federation, 193163
Novartis Investigative Site
Yaroslavl, Russian Federation, 150003
Singapore
Novartis Investigative Site
Singapore, Singapore, 168752
Novartis Investigative Site
Singapore, Singapore, 768825
Novartis Investigative Site
Singapore, Singapore, 119074
Slovakia
Novartis Investigative Site
Liptovsky Mikulas, Slovak Republic, Slovakia, 831 23
Novartis Investigative Site
Presov, Slovak Republic, Slovakia, 081 81
Novartis Investigative Site
Bratislava, Slovakia, 813 69
Novartis Investigative Site
Bratislava, Slovakia, 833 48
Novartis Investigative Site
Komarno, Slovakia, 94575
Novartis Investigative Site
Kosice, Slovakia, 040 01
Novartis Investigative Site
Kosice-Saca, Slovakia, 040 01
Novartis Investigative Site
Levice, Slovakia, 934 01
Novartis Investigative Site
Lucenec, Slovakia, 984 39
Novartis Investigative Site
Martin, Slovakia, 036 59
Novartis Investigative Site
Nitra, Slovakia, 949 01
Novartis Investigative Site
Trnava, Slovakia, 917 75
Spain
Novartis Investigative Site
Sanlúcar de Barrameda, Andalucia, Spain, 11540
Novartis Investigative Site
Villamartin, Andalucia, Spain, 11650
Novartis Investigative Site
Palma de Mallorca, Baleares, Spain, 07010
Novartis Investigative Site
Barcelona, Cataluña, Spain, 08003
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46014
Novartis Investigative Site
Santiago de Compostela, Galicia, Spain, 15706
Novartis Investigative Site
Majadanonda, Madrid, Spain, 28220
Novartis Investigative Site
Pozuelo de Alarcón, Madrid, Spain, 28223
Novartis Investigative Site
Madrid, Spain, 28040
Novartis Investigative Site
Madrid, Spain, 28007
Novartis Investigative Site
Madrid, Spain, 28046
Sweden
Novartis Investigative Site
Göteborg, Sweden, 416 85
Novartis Investigative Site
Stockholm, Sweden, 118 83
Novartis Investigative Site
Stockholm, Sweden, 182 88
Novartis Investigative Site
Stockholm, Sweden, 141 86
Taiwan
Novartis Investigative Site
Kaohsiung, Taiwan, 807
Novartis Investigative Site
Keelung City, Taiwan, 20401
Novartis Investigative Site
Lin-Ko, Taiwan, 33305
Novartis Investigative Site
Taichung, Taiwan, 40447
Novartis Investigative Site
Taipei, Taiwan, 112
Novartis Investigative Site
Taipei, Taiwan
Turkey
Novartis Investigative Site
Ankara, Turkey, 06500
Novartis Investigative Site
Atakum / Samsun, Turkey, 55139
Novartis Investigative Site
Etlik / Ankara, Turkey, 06018
Novartis Investigative Site
Istanbul, Turkey, 34304
Novartis Investigative Site
Istanbul, Turkey, 34303
Novartis Investigative Site
Izmir, Turkey, 35040
Novartis Investigative Site
Izmir, Turkey, 35340
Novartis Investigative Site
Kirikkale, Turkey, 71100
Novartis Investigative Site
Kocaeli, Turkey, 41380
Novartis Investigative Site
Sivas, Turkey, 58140
Novartis Investigative Site
Talas / Kayseri, Turkey, 38039
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Study Director: Novartis Novartis
  More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT00894387     History of Changes
Other Study ID Numbers: CSPP100A2368, 2009-010236-18
Study First Received: May 5, 2009
Results First Received: August 2, 2013
Last Updated: October 15, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
elevated BNP
reduced LVEF
Acute Heart Failure
Cardiovascular death
CHF
hospitalization
morbi-mortality trial
outcome study
endpoint driven
plasma renin activity
renin angiotensin
aldosterone system
direct renin inhibitors
BNP
KCCQ
eGFR

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on September 22, 2014